Gennex Laboratories (BOM:531739) EBIT: ₹277 Mil (TTM As of Mar. 2026)


BOM:531739 Gennex Laboratories Ltd BOM:531739
81 GF Score
Price ₹10.16
GF Value ₹15.43
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Gennex Laboratories EBIT?

Gennex Laboratories BOM:531739 -1.74% 81 EBIT is ₹277 Mil as of Mar. 2026. GuruFocus rates BOM:531739 with a GF Score™ of 81/100 and a GF Value™ of ₹15.43 (Possible Value Trap). The stock has 7 warning signs investors should review.

Gennex Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹277 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Gennex Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 11.44%. Gennex Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 17.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Gennex Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 15.86%.


Gennex Laboratories  (BOM:531739) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Gennex Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=189.016 * ( 1 - 4.21% )/( (0 + 1582.511)/ 1 )
=181.0584264/1582.511
=11.44 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3486.752 - 287.605 - ( 1616.636 - max(0, 723.99 - 2646.559+1616.636))
=1582.511

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Gennex Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=241.764/( ( (0 + max(0, 0)) + (711.14 + max(665.47, 0)) )/ 1 )
=241.764/( ( 0 + 1376.61 )/ 1 )
=241.764/1376.61
=17.56 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(435.565 + 538.875 + 55.483) - (287.605 + 0 + 76.848)
=665.47

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Gennex Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=277.358/1748.484
=15.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gennex Laboratories EBIT Related Terms


Gennex Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Gennex Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gennex Laboratories EBIT Chart

Gennex Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.71 77.27 195.68 251.57 280.36

Gennex Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.05 68.45 70.91 77.56 60.44

BOM:531739 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gennex Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gennex Laboratories EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gennex Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gennex Laboratories's EV-to-EBIT falls into.


BOM:531739
81GF Score
Gennex Laboratories Ltd BOM:531739
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gennex Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹277 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹277 Mil mean?
Gennex Laboratories (BOM:531739) has a EBIT of ₹277 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Gennex Laboratories.
Is Gennex Laboratories' EBIT too high?
Gennex Laboratories' current EBIT is ₹277 Mil. Overall, Gennex Laboratories has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gennex Laboratories' EBIT compare to ZTS and UTHR?
Gennex Laboratories' EBIT of ₹277 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Gennex Laboratories. Gennex Laboratories's current EBIT is ₹277 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gennex Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Gennex Laboratories (BOM:531739) is currently considered Possible Value Trap. The stock's GF Value™ is ₹15.43, compared to a current price of ₹10.16 — trading 34.2% below its estimated fair value. The current EBIT is ₹277 Mil. Gennex Laboratories' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Gennex Laboratories (BOM:531739), the current EBIT is ₹277 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gennex Laboratories (BOM:531739) Overvalued in 2026?

Based on GuruFocus' analysis, Gennex Laboratories stock appears to be undervalued. The current stock price of ₹10.16 is trading 34.2% below its estimated GF Value™ of ₹15.43. GuruFocus considers Gennex Laboratories to be Possible Value Trap.

Key valuation signals for BOM:531739:

  • EBIT: ₹277 Mil
  • GF Value™: ₹15.43 vs. price of ₹10.16 (34.2% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the BOM:531739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gennex Laboratories Business Description

Address Akash Ganga, Plot No. 144, 4th Floor, Srinagar Colony, Hyderabad, TG, IND, 500 073
Gennex Laboratories Ltd is engaged in the manufacturing of bulk drugs, and intermediates, Biotech Products. Geographically, the group has a business presence in Bangladesh, Egypt, Germany, Guatemala, Iran, Israel and other countries. Its products include Guaifenesin, Methocarbamol, Fluconazole and Phenazopyridine, among others.
81GF Score

Get the complete analysis for BOM:531739

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.16
Price
₹15.43
GF Value